Analyses of pretherapy peripheral immunoscore and response to vaccine therapy

Cancer Immunology Research

Volumn 4, Issue 9, 2016, Pages 755-765

  Farsaci, Benedetto ^a   Donahue, Renee N ^a   Grenga, Italia ^a   Lepone, Lauren M ^a   Kim, Peter S ^a   Dempsey, Brendan ^a   Siebert, Janet C ^b   Ibrahim, Nuhad K ^c   Madan, Ravi A ^a   Heery, Christopher R ^a   Gulley, James L ^a   Schlom, Jeffrey ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CytoAnalytics   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; FALIMAREV; LEXIDRONAM SAMARIUM SM 153; RILIMOGENE GALVACIREPVEC; BIOLOGICAL MARKER; CANCER VACCINE;

ARTICLE; BONE METASTASIS; CANCER IMMUNIZATION; CANCER PROGNOSIS; CELL SUBPOPULATION; HUMAN; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MYELOID-DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SCORING SYSTEM; TREATMENT RESPONSE; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MONONUCLEAR CELL; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; TREATMENT OUTCOME;

BIOMARKERS; CANCER VACCINES; CLUSTER ANALYSIS; COMBINED MODALITY THERAPY; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; NEOPLASMS; TREATMENT OUTCOME;

EID: 85016143630     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0037     Document Type: Article

References (56)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
2. Koelzer VH, Lugli A, Dawson H, Hadrich M, Berger MD, Borner M, et al. CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival. J Transl Med 2014;12:81.
3. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012;10:205.
4. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306.
5. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 2011;236:567-79.
6. Mahnke YD, Roederer M. Optimizing a multicolor immunophenotyping assay. Clin Lab Med 2007;27:469-85, v.
7. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
8. Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 2014;3: e29244.
9. Czystowska M, Gooding W, Szczepanski MJ, Lopez-Abaitero A, Ferris RL, Johnson JT, et al. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin Cancer Res 2013;19:889-99.
10. Jordan KR, Amaria RN, Ramirez O, Callihan EB, Gao D, Borakove M, et al. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother 2013;62:1711-22.
11. Schueneman AJ, Sugar EA, Uram J, Bigelow E, Herman JM, Edil BH, et al. Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine. Ann Surg Oncol 2013;20Suppl 3: S725-30.
12. Dang Y, Disis ML. Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer. Ann N Y Acad Sci 2009;1174:81-7.
13. Arlen PM, Pazdur M, Skarupa L, Rauckhorst M, Gulley JL. A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer 2006;7:176-9.
14. Heery CR, Madan RA, Bilusic M, Kim JW, Singh NK, Rauckhorst M, et al. Interim analysis of a phase II randomized clinical trial of samrium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castrationresistant prostate cancer after docetaxel. 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO). J Clin Oncol 201230; (suppl; abstr 2526).
15. Heery CR, Madan RA, Bilusic M, Kim JW, Singh NK, Rauckhorst M, et al. A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. 2013 ASCO Genitourinary Cancers Symposium. J Clin Oncol 2013;31; (suppl 6; abstr 102).
16. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013;133:624-36.
17. Gameiro SR, Ardiani A, Kwilas A, Hodge JW. Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology 2014;3:e28643.
18. Lepone LM, Donahue RN, Grenga I, Metenou S, Richards J, Heery CR, et al. Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune cell types. J Circ Biomark 2016;5; doi: 10.5772/62322.
19. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005;102:9571-6.
20. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009;10:29-37.
21. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010;207:2175-86.
22. Kleinewietfeld M, Starke M, Di Mitri D, BorsellinoG, Battistini L, Rotzschke O, et al. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood 2009;113:827-36.
23. Kraczyk B, Remus R, Hardt C. CD49d Treg cells with high suppressive capacity are remarkably less efficient on activated CD45RA than on naive CD45RA+ Teff cells. Cell Physiol Biochem 2014;34:346-55.
24. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, et al. Sunitinibmediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
25. Zhang B, Wang Z,WuL, Zhang M, Li W, Ding J, et al. Circulating and tumorinfiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 2013;8:e57114.
26. Gogali F, Paterakis G, Rassidakis GZ, Liakou CI, Liapi C. CD3(-)CD16(-) CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. Thyroid 2013;23:1561-8.
27. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res 2006;12:718-25.
28. Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014;124:99-110.
29. Gleason MK, Lenvik TR, McCullar V, Felices M, O'Brien MS, Cooley SA, et al. Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood 2012; 119:3064-72.
30. Shen T, Chen X, Chen Y, Xu Q, Lu F, Liu S. Increased PD-L1 expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection. J Med Virol 2010;82:1152-9.
31. Maine CJ, Aziz NH, Chatterjee J, Hayford C, Brewig N, Whilding L, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother 2014;63:215-24.
32. Noman MZ, Desantis G, Janji B,Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014;211:781-90.
33. Siebert JC, Wang L, Haley DP, Romer A, Zheng B, Munsil W, et al. Exhaustive expansion: a novel technique for analyzing complex data generated by higher-order polychromatic flow cytometry experiments. J Transl Med 2010;8:106.
34. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, et al. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol 2015;1:1087-95.
35. Heery CR, Madan RA, Stein MN, Stadler WM, DiPaola RS, Rauckhorst M, et al. Samarium-153-EDTMP (Quadramet) with or without vaccine in metastatic castration-resistant prostate cancer: a randomized phase 2 trial. Oncotarget 2016;in press.
36. Halama N, Michel S, Kloor M, Zoernig I, Benner A, Spille A, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011;71:5670-7.
37. Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J 2010;16:399-403.
38. Cancer Research Institute, Timeline of Progress. [cited 2016 2/17/2016]; Available from: http://www.cancerresearch.org/our-strategy-impact/timeline-of-progress/timeline-detail.
39. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res 2014;20:6258-68.
40. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviralbased vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008;14:3060-9.
41. Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, et al. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther 2011;11:1409-18.
42. Morse MA, NiedzwieckiD,Marshall JL,Garrett C, Chang DZ, Aklilu M, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013;258:879-86.
43. Gulley JL, Madan RA, Tsang KY, Jochems C, Marte JL, Farsaci B, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res 2014; 2:133-41.
44. Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 doseescalation trial. Lancet Oncol 2012;13:501-8.
45. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36.
46. Veeramani S, Wang SY, Dahle C, Blackwell S, Jacobus L, Knutson T, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-Affinity CD16 polymorphism. Blood 2011; 118:3347-9.
47. Lotze MT, Thomson AW. Measuring immunity: basic science and clinical practice: London, UK: Elsevier Academic Press; 2011.
48. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
49. Tai X, Van Laethem F, Pobezinsky L, Guinter T, Sharrow SO, Adams A, et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 2012;119:5155-63.
50. Jochems C, Tucker JA, Tsang KY, Madan RA, Dahut WL, Liewehr DJ, et al. A combination trial of vaccine plus ipilimumab in metastatic castrationresistant prostate cancer patients: immune correlates. Cancer Immunol Immunother 2014;63:407-18.
51. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.
52. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
53. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 2015;112:95-102.
54. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28.
55. Schmidt LH, Kummel A, Gorlich D,Mohr M, Brockling S, Mikesch JH, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One 2015;10:e0136023.
56. Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 2015;6:14209-19.